Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Post by dt_coreon Mar 27, 2022 2:42pm
182 Views
Post# 34550030

Insider Selling

Insider SellingOn March 23 when the stock traded about 70K shares in total and went from 1.16 to 1.06 two insiders sold just over 50K shares. Jae Cornelssen (CF) sold 34,477 shares and Steward Gill (Legal Counsel) sold 16,229. I suspect these were automated sales though not certain. Having insiders sell what essentially equates to near the daily volume on this stock at whatever price just crushed the shares and insiders likely aren't allowed to buy until they report earnings.

Think Research is a thinly traded stock and these pre-planed insider sales, especially if automated, continue to illustrate managements lack of acumen at running a public company and supporting the share price. I'm hopeful Oak Hill can help them here but why would they until later in April? Afterall Oak Hill is going to get their first payments in shares so it's in their interest to have the share price as low as possible since that will maximize the number of shares they earn and then later promote the price... again another poor capital management decision by THNK leadership.
<< Previous
Bullboard Posts
Next >>